Thus, inhibition of Her2, EGFR, or their downstream effectors can intercept the sensitive mutp53-HSF1-Her2/EGFR circuitry and therefore be a potent approach for the treatment of Her2 (or EGFR) and mutp53 double-positive cancers. The gene discussed is HSF1; the disease is cancer.